The Company enGene (NASDAQ: ENGN) is a late-stage biotechnology company mainstreaming genetic medicines through the...) who are unresponsive to BCG. Detalimogene voraplasmid was developed using enGene's proprietary Dually Derivatized...
enGene (NASDAQ: ENGN) is a late-stage biotechnology company mainstreaming genetic medicines through the delivery... are unresponsive to BCG. Detalimogene voraplasmid was developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX...